UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Multiple primary malignancies among patients with advanced melanoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e22531-e22531

2021

Volltextzugriff (PDF)

Examination of mutation signature and mutation spectrum as predictors of response to immune checkpoint blockade therapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2537-2537

2022

Volltextzugriff (PDF)

Venous thromboembolism in patients on check point inhibitors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e14582-e14582

2021

Volltextzugriff (PDF)

Immunohistochemical analysis of the tumor microenvironment in acral lentiginous melanoma (ALM)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21588-e21588

2023

Volltextzugriff (PDF)

Long-term outcomes of PD-1 blockade in metastatic or unresectable cutaneous squamous cell cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21551-e21551

2023

Volltextzugriff (PDF)

Impact of steroid use among patients with renal cell carcinoma (RCC) who develop immune-related adverse events (irAE)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4530-4530

2022

Volltextzugriff (PDF)

Impact of ethnicity and immune-related adverse events (IRAE) on outcomes for non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21115-e21115

2022

Volltextzugriff (PDF)

CLO22-062: The Impact of COVID-19 Infection Among Genitourinary Cancer Patients in Los Angeles County: A Retrospective Analysis

Journal of the National Comprehensive Cancer Network, 2022-03, Vol.20 (3.5), p.CLO22-062

2022

Volltextzugriff (PDF)

COVID-19 outcomes in patients with a history of breast cancer: A diverse multicenter Los Angeles cohort study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e12544-e12544

2021

Volltextzugriff (PDF)

Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9517-9517

2024

Volltextzugriff (PDF)

A phase 1 trial in progress for in situ immunomodulation with CDX-301, radiation therapy, poly-ICLC, and CDX-1140 in patients with unresectable and metastatic solid tumors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS2697-TPS2697

2024

Volltextzugriff (PDF)

Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9505-9505

2024

Volltextzugriff (PDF)

Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9565-9565

2022

Volltextzugriff (PDF)

Clinical experience with dermatofibrosarcoma protuberans (DFSP) in a diverse ethnic population

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e23531-e23531

2018

Volltextzugriff (PDF)

PD-1 inhibition in cutaneous squamous cell carcinoma (cSCC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e15100-e15100

2018

Volltextzugriff (PDF)

Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9511-9511

2023

Volltextzugriff (PDF)

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9509-9509

2023

Volltextzugriff (PDF)

Assessing somatic and germline variants in cancer patients

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.10601-10601

2021

Volltextzugriff (PDF)

Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9537-9537

2021

Volltextzugriff (PDF)

Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9502-9502

2022

Volltextzugriff (PDF)

Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9553-9553

2022

Volltextzugriff (PDF)

Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9524-9524

2022

Volltextzugriff (PDF)

Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1034-1034

2021

Volltextzugriff (PDF)

Molecular profiling of melanoma brain metastases (MBM) compared to primary cutaneous melanoma (CM)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9565-9565

2019

Volltextzugriff (PDF)

Clinical characteristics of melanoma in an ethnically diverse population of adolescents and young adults

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e21043-e21043

2017

Volltextzugriff (PDF)

1 – 25 von 187

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(162)
Mit Volltextzugriff
(167)

Publikationsform

Sprache

Englisch
(184)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(116)
Life Sciences & Biomedicine
(75)
Humans
(41)
Technology
(39)
Computer Science
(24)
Animals
(21)
Male
(21)
Engineering
(19)
Orthopedics
(19)
Female
(18)
Mice
(16)
Cell Biology
(11)
Computer Science, Artificial Intelligence
(11)
Computer Science, Theory & Methods
(11)
Biochemistry & Molecular Biology
(10)
Ankle
(9)
Biological And Medical Sciences
(9)
Computer Science, Cybernetics
(8)
Social Sciences
(8)
Talus
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Multiple primary malignancies among patients with advanced melanoma

Examination of mutation signature and mutation spectrum as predictors of response to immune checkpoint blockade therapy

Venous thromboembolism in patients on check point inhibitors

Immunohistochemical analysis of the tumor microenvironment in acral lentiginous melanoma (ALM)

Long-term outcomes of PD-1 blockade in metastatic or unresectable cutaneous squamous cell cancer

Impact of steroid use among patients with renal cell carcinoma (RCC) who develop immune-related adverse events (irAE)

Impact of ethnicity and immune-related adverse events (IRAE) on outcomes for non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors

CLO22-062: The Impact of COVID-19 Infection Among Genitourinary Cancer Patients in Los Angeles County: A Retrospective Analysis

COVID-19 outcomes in patients with a history of breast cancer: A diverse multicenter Los Angeles cohort study

Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial

A phase 1 trial in progress for in situ immunomodulation with CDX-301, radiation therapy, poly-ICLC, and CDX-1140 in patients with unresectable and metastatic solid tumors

Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A

Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors

Clinical experience with dermatofibrosarcoma protuberans (DFSP) in a diverse ethnic population

PD-1 inhibition in cutaneous squamous cell carcinoma (cSCC)

Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466)

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study

Assessing somatic and germline variants in cancer patients

Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma

Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512)

Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE)

Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy

Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer

Molecular profiling of melanoma brain metastases (MBM) compared to primary cutaneous melanoma (CM)

Clinical characteristics of melanoma in an ethnically diverse population of adolescents and young adults

Suchergebnisse filtern